Psilocybin for opioid use disorder — patient and recovery community perspectives

The tension you're identifying is real and important: 12-step frameworks traditionally classify all mood-altering substances as incompatible with recovery. This creates a real barrier for people interested in psilocybin-assisted treatment. Some NA/AA groups are more flexible than the official literature suggests; others are not. The conversation is happening within recovery communities but it's not settled.

I'm in long-term opioid recovery (8 years). I did a psilocybin session two years in, not for addiction specifically, but for underlying depression and trauma that I believed was driving my use. I discussed it with my sponsor who was supportive. I don't think it was a relapse — it addressed root causes in a way that MAT alone didn't. My sobriety date is unchanged. Others will define this differently.

The Hopkins opioid pilot (Johnson et al. 2014) wasn't specifically for opioids — it was for tobacco cessation, and the opioid work is more recent and ongoing. The mechanism being tested: psilocybin may reduce the craving, the dysphoria of protracted abstinence syndrome, and the trauma-driven triggers that sustain addiction cycles. Whether it actually does this at scale is what current trials are testing.